CN103238070B - 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 - Google Patents

能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 Download PDF

Info

Publication number
CN103238070B
CN103238070B CN201180057292.7A CN201180057292A CN103238070B CN 103238070 B CN103238070 B CN 103238070B CN 201180057292 A CN201180057292 A CN 201180057292A CN 103238070 B CN103238070 B CN 103238070B
Authority
CN
China
Prior art keywords
purposes
prostacyclin
medicine
endothelial
atc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180057292.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103238070A (zh
Inventor
佩尔·约翰松
西塞·赖伊·奥斯特洛夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Priority to CN201610390867.1A priority Critical patent/CN106038570A/zh
Publication of CN103238070A publication Critical patent/CN103238070A/zh
Application granted granted Critical
Publication of CN103238070B publication Critical patent/CN103238070B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201180057292.7A 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 Expired - Fee Related CN103238070B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610390867.1A CN106038570A (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
PCT/DK2011/050375 WO2012041334A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610390867.1A Division CN106038570A (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Publications (2)

Publication Number Publication Date
CN103238070A CN103238070A (zh) 2013-08-07
CN103238070B true CN103238070B (zh) 2016-06-29

Family

ID=44872128

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180057292.7A Expired - Fee Related CN103238070B (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物
CN201610390867.1A Pending CN106038570A (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610390867.1A Pending CN106038570A (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Country Status (9)

Country Link
US (1) US20130261177A1 (https=)
EP (1) EP2622354A1 (https=)
JP (1) JP2013543491A (https=)
KR (1) KR20140025303A (https=)
CN (2) CN103238070B (https=)
AU (1) AU2011307494B2 (https=)
BR (1) BR112013007849A2 (https=)
CA (1) CA2812846A1 (https=)
WO (1) WO2012041334A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2832992A1 (en) * 2011-04-19 2012-10-26 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
EP2834642A1 (en) * 2012-03-30 2015-02-11 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
WO2015073314A1 (en) 2013-11-13 2015-05-21 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog
CN107250375A (zh) 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016126849A1 (en) * 2015-02-03 2016-08-11 The Regents Of The University Of Colorado, A Body Corporate Use of viscoelastic analysis for predicting massive hemorrhage
EP3278112B1 (en) 2015-03-29 2021-09-22 Endothel Pharma ApS A composition comprising prostacyclin or analogues thereof for treatment of acute critically ill patients
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
EP3455366A4 (en) 2016-05-11 2020-02-26 Michael P. Chapman ANALYSIS OF VISCOELASTICITY IN PATIENTS WITH A DISEASE ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
US12440285B2 (en) * 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US12105099B2 (en) * 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
WO1993025220A1 (en) * 1992-06-05 1993-12-23 Reid Thomas J Iii Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
EP2525806B1 (en) * 2010-01-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Angiopoietin-like-protein-4 (ANGPTL4) for the preservation of vascular endothelial-cell barrier integrity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Effect of Bosentan on Leptin and Endothelin-1 Concentration in Plasma and Brain After Cardiac Arrest in Rats;RobertP.Ostrowski et al.;《DRUG DEVELOPMENT RESEARCH》;20050331;第64卷(第3期);137-144 *

Also Published As

Publication number Publication date
AU2011307494B2 (en) 2015-08-06
AU2011307494A1 (en) 2013-05-02
WO2012041334A1 (en) 2012-04-05
US20130261177A1 (en) 2013-10-03
KR20140025303A (ko) 2014-03-04
JP2013543491A (ja) 2013-12-05
CN106038570A (zh) 2016-10-26
CA2812846A1 (en) 2012-04-05
CN103238070A (zh) 2013-08-07
BR112013007849A2 (pt) 2016-06-07
EP2622354A1 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
CN103238070B (zh) 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Boyer et al. Postoperative acute kidney injury
Oliver et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT)
Lee et al. Anaphylaxis: mechanisms and management
ES2456043T3 (es) Receptor soluble del activador de plasminógeno de tipo uroquinasa (suPAR) como marcador predictivo de enfermedades cardiovasculares
EP2207537B1 (en) Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
JP2014514310A (ja) 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
EP4493588A1 (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
Hein et al. Functional and molecular characterization of the endothelin system in retinal arterioles
Gabrielli et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients
Tkachenko et al. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease
DK2624859T3 (en) FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
BR112020023943A2 (pt) métodos de tratamento de pacientes em risco de lesão renal e insuficiência renal
Tang et al. Prenatal betamethasone exposure alters renal function in immature sheep: sex differences in effects
Hamdy et al. Presence and quantification of neuropeptide Y in pulmonary edema fluids in rats
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
Wimmer et al. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure
Koo et al. Mechanism of hepatocellular dysfunction during sepsis: the role of gut-derived norepinephrine
Boldt et al. RETRACTED: Volume Replacement With a Balanced Hydroxyethyl Starch (HES) Preparation in Cardiac Surgery Patients
O'CONNOR et al. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol
Delesalle et al. Determination of the source of increased serotonin (5‐HT) concentrations in blood and peritoneal fluid of colic horses with compromised bowel
WO2023061946A1 (en) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass
Gallieni et al. Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients
Brainard Acquired Platelet Dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

Termination date: 20170930

CF01 Termination of patent right due to non-payment of annual fee